CliffBio
biologic

zevaskyn

Prademagene zamikeracel

Loss of exclusivityApril 2037projected — 12-year biologic exclusivity estimate
CompanyAbeona Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand namezevaskyn
Active ingredientPrademagene zamikeracel
Strength41.25CM^2
Dosage formCellular Sheet
RouteTopical
ModalityBiologic
FDA approvalApril 2025
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

zevaskyn patent cliff — loss of exclusivity April 2037 | CliffBio